Diabetic%20Dyslipidemia

1
Diabetic Dyslipidemia

• Dr. R. V. S. N. Sarma., M.D., M.Sc., (Canada)
• Consultant Physician and Chest Specialist

www.drsarma.in
2
(No Transcript)
3
(No Transcript)
4
What types of lesions cause MI ?
Coronary stenosis severity prior to MI
100
100
14
80
80
18
60
68
60
Coronary stenosis ()
40
40
20
20
0
0
All fourstudies
Ambrose1988
Little1988
Nobuyoshi1991
Giroud1992
50-70
lt50
gt70
Falk E, et al. Circulation. 199592657-671.
5
What types of lesions cause MI ?
Coronary stenosis severity prior to MI
100
100
14
80
80
18
60
68
60
Not the degree of stenosis
Coronary stenosis ()
40
40
20
20
0
0
All fourstudies
Ambrose1988
Little1988
Nobuyoshi1991
Giroud1992
50-70
lt50
gt70
Falk E, et al. Circulation. 199592657-671.
6
CV Risk Factors in Diabetes
12
10.0
10
8
6.5
Odds Ratio
6
3.2
4
2.3
2
0
Microalbuminuria
Smoking
Diastolic BP
Cholesterol
Eastman RC, Keen H. Lancet 1997350 Suppl 129-32.
7
Causes of death in Diabetes
8
Diabetes Coronary A D

• Why is it so ?

9
DM Strongest RF for CVD
DM CHD
10
Duration of T2DM and CVD
48
29
24
21
15
2
3-5
6-9
10-14
15
Years after DM Diagnosis
Harris, S et al. Type 2 Diabetes and Associated
Complications in Primary Care in Canada The
Impact of Duration of Disease on Morbidity Load.
CDA 2003.
11
Duration of DM - CV Mortality
4
p for trend lt0.001
3.5
3
2.5
Relative Risk
2
1.5
1
0.5
0
lt 5
6 to 10
11 to 15
16 to 25
26
Duration of Diabetes (years)
Cho, et al. J Am Coll Card 200240954.
12
Life Expectancy with Diabetes
Years
DM
90
No DM
1600
80
1400
70
1200
60
Diabetes
1000
No Diabetes
50
800
40
600
30
400
20
200
10
0
0
Mortality rate/100,000
Men
Women
Hux JE, et al. Diabetes in Ontario, an ICES
Practice Atlas 2003.
13
Cardiovascular Disease and T2DM
20
Diabetes
15
No Diabetes
10
Prevalence of CV Disease
5
0
Hypertension
Heart Disease
Hux JE, et al. Diabetes in Ontario, an ICES
Practice Atlas 2003.
14
Clinical Outcome for Diabetes 4-year Follow-up
14
12
10
8

6
4
2
0
CV Death
MI
Stroke
Dialysis
HOPE / MICRO-HOPE. Lancet 2000355253.
15
ACS and Diabetes Up to 1 Year
25
Plt0.0001
No Diabetes
20
21.3
N 3429
Plt0.0001
Diabetes
15
N 1149
of patients
14.4
14.1
P0.035
10
8.9
7.9
Plt0.0001
7.1
5
3.9
1.8
0
In-Hospital
Non-fatal MI
1-y All-Cause
1-y
Mortality
Mortality
Mortality/MI
Yan R, et al. Can J Cardiol 200319(suppl
A)260A.
16
OASIS Study Total Mortality
0.25
Diabetes/CVD , (n 1148)
RR 2.88 (2.37-3.49)
Diabetes/CVD -, (n 569)
0.20
No Diabetes/CVD , (n 3503)
No Diabetes/CVD -, (n 2796)
RR1.99 (1.52-2.60)
0.15
Event rate
0.10
RR1.71 (1.44-2.04)
0.05
RR1.00
0.0
Months ?
3 6 9 12 15 18
21 24
Malmberg K, et al. Circulation 200010210141019.
17
Predictors of CV Risk in DM
18
DM CAD - Because

• CVD is responsible for 60 - 75 of mortality in
  T2DM
• CVD is 4 times more prevalent in diabetes CADI
  is more
• CVD prevalence increases with age, so is T2DM
• CVD in DM is often severe, silent, poor prognosis
  and fatal
• Diabetes ? mortality, 50 pre adm / recurrent MI
  and ACS
• Diabetes erases the protection conferred to women
• At diagnosis of T2DM, most patients have evidence
  of CVD
• Abnormal Glucose tolerance is a strong CV Risk
  factor

19
The Lipid Profile

• How to interpret ?

20
Lipoproteins
LDL
VLDL
20
21
Atherogenic Particles
Non-HDL-C
Measurements
Apolipoprotein B
VLDL
VLDLR
IDL
LDL
SDL
TG rich particles
Cholesterol rich
21
22
The Good, Bad, Ugly and Deadly

• Total Cholesterol lt 200
• Good Cholesterols (HDL)
• HDL 1, HDL 2, HDL 3 gt 50
• Bad Cholesterols (Non HDL) lt 150
• LDL, IDL lt 100
• VLDL, VLDL-R lt 30
• Lp(a), Small LDL lt 20

HDL 1 and HDL 2 are protective
22
23
Todays Safer Values

• Total Cholesterol lt 200
• Triglycerides lt 150
• LDL Cholesterol lt 100 preferably lt 70
• HDL Cholesterol gt 50 (for women 55)
• Bad Cholesterols the lower the better
• Good Cholesterols the higher the better
• Non HDL Cholesterol lt 130
• Lp(a) values lt 20

24
Dyslipidemia in Diabetes

• What are the Mechanisms ?

25
Atherosclerosis and Insulin Resistance
Hypertension Obesity Hyperinsulinemia Diabetes Hyp
er triglyceridemia Small, dense LDL Low HDL Hyper
coagulability
InsulinResistance
Atherosclerosis
26
Insulin Resistance - Clinical Clues

• Abdominal obesity
• ? TG ? HDL-C
• Glucose intolerance
• Hypertension
• Atherosclerosis
• Ethnicity (Indians, Negroid races)

27
Dyslipidemia in DM and IRS

• Elevated total TG
• Reduced HDL
• Small, dense LDL
• ? HDL 3 and ? HDL1 and HDL 2
• LDL is not usually high
• Postprandial Hyper lipemia

LDL Level of 180 to 220 mg
28
Dyslipidemia in DM and IRS
Increased
Decreased

• Triglycerides
• VLDL
• LDL, sLDL
• Apo B

• HDL
• Apo A-I

29
Dyslipidemia based on TG and LDL
30
Dyslipidemia based on TG and Apo B
31
Mechanisms of DM Dyslipidemia
Fat Cells
Liver
?FFA
X
IR
Insulin
32
Mechanisms of DM Dyslipidemia
Fat Cells
Liver
?FFA
? TG ? Apo B ? VLDL
VLDL
X
IR
Insulin
33
Mechanisms of DM Dyslipidemia
Fat Cells
Liver
?FFA
CE
(hepaticlipase)
? TG ? Apo B ? VLDL
(CETP)
HDL
?VLDL
X
IR
TG
Apo A-1
Kidney
Insulin
34
Mechanisms of DM Dyslipidemia
Fat Cells
Liver
?FFA
CE
(hepaticlipase)
? TG ? Apo B ? VLDL
(CETP)
HDL
?VLDL
X
IR
TG
Apo A-1
(CETP)
TG
CE
Kidney
Insulin
SDLDL
LDL
(lipoprotein or hepatic lipase)
35
IR and TG Increase
Insulin Response to Oral Glucose
Olefsky JM et al. Am J Med. 197457551-560.
36
DM, IRS and HDL
Hyperinsulinemic Normoinsulinemic
P lt 0.005
P lt 0.005
HDL-C (mg/dL)
Non-obese
Obese
Reaven GM. In Le Roith D et al., eds. Diabetes
Mellitus.1996509-519.
37
Effects of ? TG on CV Risk

• Accumulation of chylomicron remnants
• Accumulation of VLDL remnants
• Generation of small, dense LDL
• Association with low HDL
• Increased coagulability
• ? PAI-1, and ? factor VIIc
• Activation of prothrombin to thrombin

38
Small Dense LDL and CHD Potential Atherogenic
Mechanisms

• Increased susceptibility to oxidation
• Increased vascular permeability
• Conformational change in Apo B
• ? Affinity for LDL receptor (? clearance)
• Association with insulin resistance syndrome
• Association with high TG and low HDL

Austin MA et al. Curr Opin Lipidol 19967167-171.
39
Research on DM Dyslipidemia

• What the studies say ?

40
(No Transcript)
41
(No Transcript)
42
(No Transcript)
43
(No Transcript)
44
Multiplicative Effect
45

• Clear Excess mortality in DM

46
Vascular Protection in DM

• A New Paradigm !!!

47
Glycemic control alone

• is hopelessly inadequate !!

48
The A B C of Diabetes Management

• A A1c (Hb A1c)
• B Blood pressure (goal)
• C Cholesterol (all lipids)

49
Ticking Clock of T2DM

• Micro-vascular (DR, DKD, DPN, DAN)
• At the onset of hyperglycemia
• Control of hyperglycemia essential
• The A1c target of less than 7 must (A)
• Macro-vascular (CAD, CVD, PVD)
• At the onset of insulin resistance
• Blood pressure goal of 130/80 (B)
• Control of lipid abnormalities (C)

50
(No Transcript)
51
Goals inT2DM for VP
Risk Factor Goal or Target
Glycemia Hb A1c lt 6.5
Blood Pressure lt 130/80 mm Hg
LDL target lt 100 mg better lt 70
HDL target gt 40 men, gt 50 women
TG target lt 150 mg
BMI lt 25 kg/m2
Physical activity At least 5 days - 2 km/day
ADA, CDA, IDF, WWD
52
From Blood Sugar to Blood Vessel
ACEi (Ramipril) Vasoprotective, anti HT, ? ED
ASA (75 to 150 mg) Anti inflamm., Anti Platelet
Statin (Powerful, full) ? LDL, TG, Corrects ED, Inflam
BP Goal Vascular damage, LVH, CVA
Glycemic control ? Micro vascular ? Macrovascular
Physical activity ED, ? Inflammation, ? HDL
Diet and TLC ? TG, LDL, Glycemia, Weight
Smoking cessation ? ED and Inflammation
53
ACEi in T2DM - VP

• Antihypertensive, vasoprotective, antithrombotic,
  and anti-inflammatory properties
  Inevitable in DM
• Reduce CV events, Reduce atherosclerosis
• Reduce renal disease which is a strong CV risk
  factor
• Metabolically friendly drugs that prevent
  rises in glucose prevent diabetes
• Well-tolerated with few side effects

54
Treatment of DM Dyslipidemia

• Recommendations

55
MNT and Dyslipidemia

• Total CHO to be reduced lt 50 of calories
• Saturated fat must reduced tolt 7 of calories
• MUFA and PUFA up to 15 of calories
• Protein in take to be increased 25 of cal.
• Dietary fiber gt 20 g/day -Soy protein, Fenugreek
• Vegetables, Nuts and fruits must every day

56
Priorities for Treatment

• If all lipid values are normal
• Lifestyle interventions (TLC)
• MNT, Physical Activity, Weight and Waist
  reduction
• Statin in a minimum dose of 10 mg o.d
• Follow up every one year by full lipid profile
• All Indians must be tested for LP(a) and
• If gt 30 mg - Niacin SR 350 to 500 mg started

57
Priorities for Treatment

• LDL cholesterol lowering First priority
• Lifestyle interventions (TLC)
• Drugs - First choice Statin with or without
• Cholesterol absorption inhibitors (EZ)
• Second choice Niacin and Fibrate
• Add on BAR (Bile acid binding resins)

58
Priorities for Treatment

• HDL cholesterol raising Second priority
• Lifestyle interventions
• First choice - Niacin ( doses lt2 g/day)
• Preferably short acting Niacin
• Fibrates are second choice

59
Priorities for Treatment

• Triglyceride lowering Third priority
• First choice Lifestyle interventions
• Glycemic control is the best Rx for ?TG
• Fibrates
• Niacin
• High dose statins (if LDL is also high )

60
Priorities for Treatment

• Triglyceride Lowering (continued)
• In case of severe hyper triglyceridemia (gt 1000
  mg), severe fat restriction (lt 10 of calories )
  in addition to pharmacological therapy is
  necessary to reduce the risk of pancreatitis
  and lipemia effects

61
Priorities for Treatment

• Combined Dyslipidemia
• First choice Glycemic control Statin
• Glycemic control Statin Fibrate
• Glycemic control Statin Niacin

62
Drug Rx. Effect on Lipoproteins
Pharmacological Agents LDL HDL TG
Statins (HMG CoA Reductase In) ? ? ? ? ? ?
Fibrates (PPAR- ? Activators) ? ? ? ? ?
BAR (Bile Acid Sequestering Resins) ? ? ?
Niacin (Plain or SR) ? ? ? ? ?
ADA. Diabetes Care 200326 (suppl 1)S 83-S 86
63
Drugs for Dyslipidemia
64
Treatment of ? LDL
High LDL
Therapeutic Lifestyle Change
Drug Therapy
Therapy of Choice Statin
Add on drug - EZ , Niacin, BAR
65
Treatment of ? HDL
Low HDL
Therapeutic Lifestyle Change
Drug Therapy
Therapy of Choice Niacin
Add on drug - Finofibrate
66
Treatment of ? TG
High TG
Therapeutic Lifestyle Change
Drug Therapy
Therapy of Choice Fibrate
Add on drug Statin, Niacin
67
Anti Diabetic Drugs and Lipids
Anti Diabetic Agents LDL HDL TG LDL Size
Metformin (Mildly favourable) ? ? ? ?
Pioglitazone (Very favourable) ? ? ? ? ? ?
Rosiglitazone (less favourable) ? ? ? ?
Sulfonylureas (Unfavourable) ? ? ? ?
Insulin (Not Atherogenic at all) ? ? ? ?
68
(No Transcript)
69
Anti HT Drugs and Lipids
Anti hypertensive agents On Lipids
ACEi and ARBS (Excellent) ? ?
CCBs (Neutral on lipids) ?
Diuretics (Unfavourable) ?
? Blockers (Very unfavourable) ? ?
? Blockers (Mildly unfavourable) ?
70
To Reiterate

• Glycemic goal alone is not adequate at all
• CAD must be prevented at all costs
• The A, B, C of Diabetes must be addressed
• Statins in full dose ? Fibrate or Niacin
• All T2DM must receive drugs/advise on
• ACEi/ARB, ASA, Statin, TLC, PA, ? Weight

71
Thank you all